Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer
Introduction:This study aimed to investigate the survival, treatment-related toxicities, and prognostic factors in the elderly (≥65) with prostate cancer treated with definitive radiotherapy (RT). Patients divided into two groups as young-old (65-74 years) and old (over 75 years) were examined.Metho...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2021-11-01
|
| Series: | İstanbul Medical Journal |
| Subjects: | |
| Online Access: |
http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/comparison-of-definitive-radiotherapy-in-the-young/49718
|
| _version_ | 1828029235030130688 |
|---|---|
| author | Berrin İnanç Özlem Mermut Begüm Ökten Özlem Beşikçi Ebru Tuncay Caner Aktaş |
| author_facet | Berrin İnanç Özlem Mermut Begüm Ökten Özlem Beşikçi Ebru Tuncay Caner Aktaş |
| author_sort | Berrin İnanç |
| collection | DOAJ |
| description | Introduction:This study aimed to investigate the survival, treatment-related toxicities, and prognostic factors in the elderly (≥65) with prostate cancer treated with definitive radiotherapy (RT). Patients divided into two groups as young-old (65-74 years) and old (over 75 years) were examined.Methods:A total of 178 patients with prostate cancer treated with definitive RT were retrospectively reviewed. The prognostic factors for survival, metastasis-free survival (MFS), biochemical recurrence-free survival (BFS), and treatment-related toxicities were analyzed.Results:Pretreatment prostate-specific antigen (PSA), last PSA value, and Charlson comorbidity score (5-6) were significantly different between the two groups (p=0.001, p=0.004, and p=0.012, respectively). The elderly showed high pretreatment PSA, last PSA value, and Charlson comorbidity score (5-6). None of the other treatment or patient characteristics differed significantly between the groups. The median follow-up time was 68 months (range: 12-116 months) for the young-elderly. The 5-year overall survival (OS), BFS, and MFS were 86.4%, 91.5%, and 92.8%, respectively, in the young-elderly. Median follow-up time in the elderly patients was 60 months (range: 7-118 months) and 5-year OS, MFS, and BFS rates were 79.6%, 93.1%, and 93.4%, respectively. No statistical difference was found when the OS, BFS, and MFS were evaluated in 5 years in both groups. The multivariate analysis revealed that high radiation doses (76 Gy and ≥78 Gy) and high T-stage (T3-4) was a significant prognostic factor for the BFS in all patients (p=0.013, p=0.007, and p=0.026, respectively). The presence of high-risk patients in the risk stratification was borderline significant for the BFS (p=0.051). Acute hematological toxicity, such as leucopenia (38%), and late toxicity, such as rectal bleeding (10%), were frequently observed in the elderly.Conclusion:No differences were found in the OS, BFS, and MFS between the two groups. High radiation doses and high T-stage was found as a prognostic factor for the BFS in all patients. |
| first_indexed | 2024-04-10T14:06:41Z |
| format | Article |
| id | doaj.art-88b99b250e4240c0b16fc4e6ae999f87 |
| institution | Directory Open Access Journal |
| issn | 2619-9793 2148-094X |
| language | English |
| last_indexed | 2024-04-10T14:06:41Z |
| publishDate | 2021-11-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | İstanbul Medical Journal |
| spelling | doaj.art-88b99b250e4240c0b16fc4e6ae999f872023-02-15T16:09:56ZengGalenos Yayineviİstanbul Medical Journal2619-97932148-094X2021-11-0122432633110.4274/imj.galenos.2021.2900013049054Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate CancerBerrin İnanç0Özlem Mermut1Begüm Ökten2Özlem Beşikçi3Ebru Tuncay4Caner Aktaş5 University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Radiation Oncology, İstanbul, Turkey University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Radiation Oncology, İstanbul, Turkey University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Radiation Oncology, İstanbul, Turkey University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Radiation Oncology, İstanbul, Turkey University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Radiation Oncology, İstanbul, Turkey University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Radiation Oncology, İstanbul, Turkey Introduction:This study aimed to investigate the survival, treatment-related toxicities, and prognostic factors in the elderly (≥65) with prostate cancer treated with definitive radiotherapy (RT). Patients divided into two groups as young-old (65-74 years) and old (over 75 years) were examined.Methods:A total of 178 patients with prostate cancer treated with definitive RT were retrospectively reviewed. The prognostic factors for survival, metastasis-free survival (MFS), biochemical recurrence-free survival (BFS), and treatment-related toxicities were analyzed.Results:Pretreatment prostate-specific antigen (PSA), last PSA value, and Charlson comorbidity score (5-6) were significantly different between the two groups (p=0.001, p=0.004, and p=0.012, respectively). The elderly showed high pretreatment PSA, last PSA value, and Charlson comorbidity score (5-6). None of the other treatment or patient characteristics differed significantly between the groups. The median follow-up time was 68 months (range: 12-116 months) for the young-elderly. The 5-year overall survival (OS), BFS, and MFS were 86.4%, 91.5%, and 92.8%, respectively, in the young-elderly. Median follow-up time in the elderly patients was 60 months (range: 7-118 months) and 5-year OS, MFS, and BFS rates were 79.6%, 93.1%, and 93.4%, respectively. No statistical difference was found when the OS, BFS, and MFS were evaluated in 5 years in both groups. The multivariate analysis revealed that high radiation doses (76 Gy and ≥78 Gy) and high T-stage (T3-4) was a significant prognostic factor for the BFS in all patients (p=0.013, p=0.007, and p=0.026, respectively). The presence of high-risk patients in the risk stratification was borderline significant for the BFS (p=0.051). Acute hematological toxicity, such as leucopenia (38%), and late toxicity, such as rectal bleeding (10%), were frequently observed in the elderly.Conclusion:No differences were found in the OS, BFS, and MFS between the two groups. High radiation doses and high T-stage was found as a prognostic factor for the BFS in all patients. http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/comparison-of-definitive-radiotherapy-in-the-young/49718 radiotherapyagedsurvival |
| spellingShingle | Berrin İnanç Özlem Mermut Begüm Ökten Özlem Beşikçi Ebru Tuncay Caner Aktaş Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer İstanbul Medical Journal radiotherapy aged survival |
| title | Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer |
| title_full | Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer |
| title_fullStr | Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer |
| title_full_unstemmed | Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer |
| title_short | Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer |
| title_sort | comparison of definitive radiotherapy in the young elderly and elderly with clinical localized prostate cancer |
| topic | radiotherapy aged survival |
| url |
http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/comparison-of-definitive-radiotherapy-in-the-young/49718
|
| work_keys_str_mv | AT berrininanc comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT ozlemmermut comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT begumokten comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT ozlembesikci comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT ebrutuncay comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer AT caneraktas comparisonofdefinitiveradiotherapyintheyoungelderlyandelderlywithclinicallocalizedprostatecancer |